How I treat refractory immune thrombocytopenia

Blood

Volumn 128, Issue 12, 2016, Pages 1547-1554

  Cuker, Adam ^a   Neunert, Cindy E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Och Spine at New York Presbyterian Hospitals   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ASCORBIC ACID; AZATHIOPRINE; COLCHICINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DANAZOL; DAPSONE; ELTROMBOPAG; IMMUNOGLOBULIN G; MERCAPTOPURINE; MYCOPHENOLATE MOFETIL; PREDNISONE; RETINOIC ACID; RITUXIMAB; ROMIPLOSTIM; VINBLASTINE; VINCRISTINE; IMMUNOLOGIC FACTOR;

ADULT; AGRANULOCYTOSIS; AMENORRHEA; ANOREXIA; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE DENSITY; CATARACT; CHILD; CLINICAL ARTICLE; CLINICAL OBSERVATION; CONSTIPATION; DIAGNOSTIC TEST; DIARRHEA; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; DYSPEPSIA; DYSPHORIA; EPISTAXIS; FEBRILE NEUTROPENIA; FEVER; FIBROSIS; FLU LIKE SYNDROME; GINGIVA HYPERPLASIA; HEADACHE; HEMOLYSIS; HUMAN; HYPERGLYCEMIA; HYPERTENSION; IDIOPATHIC THROMBOCYTOPENIC PURPURA; IMMUNOADSORPTION; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; INFERTILITY; INFUSION RELATED REACTION; INSOMNIA; LIVER TOXICITY; LOW DRUG DOSE; MAINTENANCE THERAPY; MALE; METHEMOGLOBINEMIA; MIDDLE AGED; MONOTHERAPY; MUSCULOSKELETAL PAIN; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEURITIS; NEUTROPENIA; OSTEOPENIA; OSTEOPOROSIS; PANCREATITIS; PARESTHESIA; PERIPHERAL NEUROPATHY; PETECHIA; PLASMA EXCHANGE; PRIORITY JOURNAL; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; RASH; RECURRENT DISEASE; REPEATED DRUG DOSE; RETINOIC ACID SYNDROME; SCHOOL CHILD; SERUM SICKNESS; SIDE EFFECT; SKIN BRUISING; SPLENECTOMY; THERAPEUTIC INDEX; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT INDICATION; TREATMENT RESPONSE; TREMOR; VIRILIZATION; WEIGHT GAIN; CASE REPORT; DRUG EFFECTS; DRUG RESISTANCE; IMMUNOLOGY; PATHOLOGY; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC;

ADRENAL CORTEX HORMONES; CHILD; DRUG RESISTANCE; HUMANS; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; PROGNOSIS; PURPURA, THROMBOCYTOPENIC, IDIOPATHIC; RITUXIMAB;

EID: 84980613358     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2016-03-603365     Document Type: Article

References (100)

1. Vesely SK, Perdue JJ, Rizvi MA, Terrell DR, George JN. Management of adult patients with persistent idiopathic thrombocytopenic purpura following splenectomy: a systematic review. Ann Intern Med. 2004;140(2):112-120.
2. Rodeghiero F, Stasi R, Gernsheimer T, et al. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009;113(11):2386-2393.
3. Neunert C, Lim W, Crowther M, Cohen A, Solberg L Jr, Crowther MA; American Society of Hematology. The American Society of Hematology 2011 evidence-based practice guideline for immune thrombocytopenia. Blood. 2011;117(16):4190-4207.
4. Kojouri K, Vesely SK, Terrell DR, George JN. Splenectomy for adult patients with idiopathic thrombocytopenic purpura: a systematic review to assess long-term platelet count responses, prediction of response, and surgical complications. Blood. 2004;104(9):2623-2634.
5. Mikhael J, Northridge K, Lindquist K, Kessler C, Deuson R, Danese M. Short-term and long-term failure of laparoscopic splenectomy in adult immune thrombocytopenic purpura patients: a systematic review. Am J Hematol. 2009;84(11):743-748.
6. McMillan R, Bussel JB, George JN, Lalla D, Nichol JL. Self-reported health-related quality of life in adults with chronic immune thrombocytopenic purpura. Am J Hematol. 2008;83(2):150-154.
7. Snyder CF, Mathias SD, Cella D, Isitt JJ, Wu AW, Young J. Health-related quality of life of immune thrombocytopenic purpura patients: results from a web-based survey. Curr Med Res Opin. 2008;24(10):2767-2776.
8. Office of Disease Prevention and Health Promotion. Health-Related Quality of Life and Well-Being. https://www.healthypeople.gov/2020/about/foundation-health-measures/Health-Related-Quality-of-Life-and-Well-Being. Accessed 31 March, 2016.
9. Provan D, Stasi R, Newland AC, et al. International consensus report on the investigation and management of primary immune thrombocytopenia. Blood. 2010;115(2):168-186.
10. Lakshmanan S, Cuker A. Contemporary management of primary immune thrombocytopenia in adults. J Thromb Haemost. 2012;10(10):1988-1998.
11. McMillan R, Durette C. Long-term outcomes in adults with chronic ITP after splenectomy failure. Blood. 2004;104(4):956-960.
12. Bourgeois E, Caulier MT, Delarozee C, Brouillard M, Bauters F, Fenaux P. Long-term follow-up of chronic autoimmune thrombocytopenic purpura refractory to splenectomy: a prospective analysis. Br J Haematol. 2003;120(6):1079-1088.
13. Neunert CE, Buchanan GR, Imbach P, et al; Intercontinental Cooperative ITP Study Group Registry II Participants. Bleeding manifestations and management of children with persistent and chronic immune thrombocytopenia: data from the Intercontinental Cooperative ITP Study Group (ICIS). Blood. 2013;121(22):4457-4462.
14. McMillan R. Classical management of refractory adult immune (idiopathic) thrombocytopenic purpura. Blood Rev. 2002;16(1):51-55.
15. Stasi R, Stipa E, Masi M, et al. Long-term observation of 208 adults with chronic idiopathic thrombocytopenic purpura. Am J Med. 1995;98(5):436-442.
16. Kavanaugh A, Wells AF. Benefits and risks of low-dose glucocorticoid treatment in the patient with rheumatoid arthritis. Rheumatology (Oxford). 2014;53(10):1742-1751.
17. Arnold DM, Dentali F, Crowther MA, et al. Systematic review: efficacy and safety of rituximab for adults with idiopathic thrombocytopenic purpura. Ann Intern Med. 2007;146(1):25-33.
18. Patel VL, Mahévas M, Lee SY, et al. Outcomes 5 years after response to rituximab therapy in children and adults with immune thrombocytopenia. Blood. 2012;119(25):5989-5995.
19. Cooper N, Evangelista ML, Amadori S, Stasi R. Should rituximab be used before or after splenectomy in patients with immune thrombocytopenic purpura? Curr Opin Hematol. 2007;14(6):642-646.
20. Zaja F, Vianelli N, Volpetti S, et al. Low-dose rituximab in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2010;85(4):329-334.
21. Koutsianas C, Thomas K, Vassilopoulos D. Prevention of HBV reactivation in patients treated with biologic agents [published online ahead of print on 6 February, 2016]. Expert Rev Clin Pharmacol.
22. Carson KR, Evens AM, Richey EA, et al. Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. Blood. 2009;113(20):4834-4840.
23. Nazi I, Kelton JG, Larché M, et al. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013;122(11):1946-1953.
24. Kuter DJ, Bussel JB, Lyons RM, et al. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008;371(9610):395-403.
25. Kuter DJ, Bussel JB, Newland A, et al. Longterm treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013;161(3):411-423.
26. Khellaf M, Michel M, Quittet P, et al. Romiplostim safety and efficacy for immune thrombocytopenia in clinical practice: 2-year results of 72 adults in a romiplostim compassionate-use program. Blood. 2011;118(16):4338-4345.
27. Bussel JB, Buchanan GR, Nugent DJ, et al. A randomized, double-blind study of romiplostim to determine its safety and efficacy in children with immune thrombocytopenia. Blood. 2011;118(1):28-36.
28. Bussel JB, Hsieh L, Buchanan GR, et al. Long-term use of the thrombopoietin-mimetic romiplostim in children with severe chronic immune thrombocytopenia (ITP). Pediatr Blood Cancer. 2014;62(2):208-213.
29. Cheng G, Saleh MN, Marcher C, et al. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011;377(9763):393-402.
30. Bussel JB, Provan D, Shamsi T, et al. Effect of eltrombopag on platelet counts and bleeding during treatment of chronic idiopathic thrombocytopenic purpura: a randomised, double-blind, placebo-controlled trial. Lancet. 2009;373(9664):641-648.
31. Saleh MN, Bussel JB, Cheng G, et al; EXTEND Study Group. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013;121(3):537-545.
32. González-López TJ, Alvarez-Román MT, Pascual C, et al. Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice [published online ahead of print 28 December, 2015]. Eur J Haematol.
33. Bussel JB, de Miguel PG, Despotovic JM, et al. Eltrombopag for the treatment of children with persistent and chronic immune thrombocytopenia (PETIT): a randomised, multicentre, placebo-controlled study. Lancet Haematol. 2015;2(8):e315-e325.
34. Grainger JD, Locatelli F, Chotsampancharoen T, et al. Eltrombopag for children with chronic immune thrombocytopenia (PETIT2): a randomised, multicentre, placebo-controlled trial. Lancet. 2015;386(10004):1649-1658.
35. Cines DB, Gernsheimer T, Wasser J, et al. Integrated analysis of long-term safety in patients with chronic immune thrombocytopaenia (ITP) treated with the thrombopoietin (TPO) receptor agonist romiplostim. Int J Hematol. 2015;102(3):259-270.
36. Brynes RK, Orazi A, Theodore D, et al. Evaluation of bone marrow reticulin in patients with chronic immune thrombocytopenia treated with eltrombopag: Data from the EXTEND study. Am J Hematol. 2015;90(7):598-601.
37. Catalá-López F, Corrales I, de la Fuente-Honrubia C, et al. Risk of thromboembolism with thrombopoietin receptor agonists in adult patients with thrombocytopenia: Systematic review and meta-analysis of randomized controlled trials. Med Clin (Barc). 2015;145(12):511-519.
38. Cuker A, Prak ET, Cines DB. Can immune thrombocytopenia be cured with medical therapy? Semin Thromb Hemost. 2015;41(4):395-404.
39. Arnold DM, Nazi I, Santos A, et al. Combination immunosuppressant therapy for patients with chronic refractory immune thrombocytopenic purpura. Blood. 2010;115(1):29-31.
40. Choi PY, Roncolato F, Badoux X, Ramanathan S, Ho SJ, Chong BH. A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4). Blood. 2015;126(4):500-503.
41. Li Y, Wang YY, Fei HR, Wang L, Yuan CL. Efficacy of low-dose rituximab in combination with recombinant human thrombopoietin in treating ITP. Eur Rev Med Pharmacol Sci. 2015;19(9):1583-1588.
42. Bussel JB, Lee CS, Seery C, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99(7):1264-1271.
43. Cui ZG, Liu XG, Qin P, et al. Recombinant human thrombopoietin in combination with cyclosporin A as a novel therapy in corticosteroid-resistant primary immune thrombocytopenia. Chin Med J (Engl). 2013;126(21):4145-4148.
44. Gómez-Almaguer D, Solano-Genesta M, Tarín-Arzaga L, et al. Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. Blood. 2010;116(23):4783-4785.
45. Williams JA, Boxer LA. Combination therapy for refractory idiopathic thrombocytopenic purpura in adolescents. J Pediatr Hematol Oncol. 2003;25(3):232-235.
46. Figueroa M, Gehlsen J, Hammond D, et al. Combination chemotherapy in refractory immune thrombocytopenic purpura. N Engl J Med. 1993;328(17):1226-1229.
47. Boruchov DM, Gururangan S, Driscoll MC, Bussel JB. Multiagent induction and maintenance therapy for patients with refractory immune thrombocytopenic purpura (ITP). Blood. 2007;110(10):3526-3531.
48. Manoharan A. Slow infusion of vincristine in the treatment of idiopathic thrombocytopenic purpura. Am J Hematol. 1986;21(2):135-138.
49. Fenaux P, Quiquandon I, Caulier MT, Simon M, Walter MP, Bauters F. Slow infusions of vinblastine in the treatment of adult idiopathic thrombocytopenic purpura: a report on 43 cases. Blut. 1990;60(4):238-241.
50. Burton IE, Roberts BE, Child JA, Montgomery DA, Raper CG. Responses to cinvristine in refractory idiopathic thrombocytopenic purpura. BMJ. 1976;2(6041):918.
51. Sikorska A, Słomkowski M, Marlanka K, Konopka L, Górski T. The use of vinca alkaloids in adult patients with refractory chronic idiopathic thrombocytopenia. Clin Lab Haematol. 2004;26(6):407-411.
52. Cervantes F, Montserrat E, Rozman C, Diumenjo C, Feliu E, Grañena A. Low-dose vincristine in the treatment of corticosteroidrefractory idiopathic thrombocytopenic purpura (ITP) in non-splenectomized patients. Postgrad Med J. 1980;56(660):711-714.
53. Stirnemann J, Kaddouri N, Khellaf M, et al. Vincristine efficacy and safety in treating immune thrombocytopenia: a retrospective study of 35 patients. Eur J Haematol. 2016;96(3):269-275.
54. Facon T, Caulier MT, Wattel E, Jouet JP, Bauters F, Fenaux P. A randomized trial comparing vinblastine in slow infusion and by bolus i.v. injection in idiopathic thrombocytopenic purpura: a report on 42 patients. Br J Haematol. 1994;86(3):678-680.
55. Ahn YS, Harrington WJ, Seelman RC, Eytel CS. Vincristine therapy of idiopathic and secondary thrombocytopenias. N Engl J Med. 1974;291(8):376-380.
56. Ahn YS, Harrington WJ, Mylvaganam R, Allen LM, Pall LM. Slow infusion of vinca alkaloids in the treatment of idiopathic thrombocytopenic purpura. Ann Intern Med. 1984;100(2):192-196.
57. Szczepanik AB, Sikorska A, Slomkowski M, Konopka L. The use of vinca alkaloids in preparation for splenectomy of corticosteroid refractory chronic immune thrombocytopenic purpura patients. Int J Lab Hematol. 2007;29(5):347-351.
58. Moss C, Hamilton PJ. Thrombocytopenia in systemic lupus erythematosus responsive to dapsone. BMJ. 1988;297(6643):266.
59. Godeau B, Durand JM, Roudot-Thoraval F, et al. Dapsone for chronic autoimmune thrombocytopenic purpura: a report of 66 cases. Br J Haematol. 1997;97(2):336-339.
60. Oo T, Hill QA. Disappointing response to dapsone as second line therapy for primary ITP: a case series. Ann Hematol. 2015;94(6):1053-1054.
61. Patel AP, Patil AS. Dapsone for immune thrombocytopenic purpura in children and adults. Platelets. 2015;26(2):164-167.
62. Rodrigo C, Gooneratne L. Dapsone for primary immune thrombocytopenia in adults and children: an evidence-based review. J Thromb Haemost. 2013;11(11):1946-1953.
63. Ahn YS, Harrington WJ, Simon SR, Mylvaganam R, Pall LM, So AG. Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med. 1983;308(23):1396-1399.
64. Ahn YS, Mylvaganam R, Garcia RO, Kim CI, Palow D, Harrington WJ. Low-dose danazol therapy in idiopathic thrombocytopenic purpura. Ann Intern Med. 1987;107(2):177-181.
65. Mylvaganam R, Ahn YS, Garcia RO, Kim CI, Harrington WJ. Very low dose danazol in idiopathic thrombocytopenic purpura and its role as an immune modulator. Am J Med Sci. 1989;298(4):215-220.
66. Edelmann DZ, Knobel B, Virag I, Meytes D. Danazol in non-splenectomized patients with refractory idiopathic thrombocytopenic purpura. Postgrad Med J. 1990;66(780):827-830.
67. Maloisel F, Andrès E, Zimmer J, et al. Danazol therapy in patients with chronic idiopathic thrombocytopenic purpura: long-term results. Am J Med. 2004;116(9):590-594.
68. Andrès E, Zimmer J, Noel E, Kaltenbach G, Koumarianou A, Maloisel F. Idiopathic thrombocytopenic purpura: a retrospective analysis in 139 patients of the influence of age on the response to corticosteroids, splenectomy and danazol. Drugs Aging. 2003;20(11):841-846.
69. Ahn YS, Rocha R, Mylvaganam R, Garcia R, Duncan R, Harrington WJ. Long-term danazol therapy in autoimmune thrombocytopenia: unmaintained remission and age-dependent response in women. Ann Intern Med. 1989;111(9):723-729.
70. Reiner A, Gernsheimer T, Slichter SJ. Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura. Blood. 1995;85(2):351-358.
71. Verlin M, Laros RK Jr, Penner JA. Treatment of refractory thrombocytopenic purpura with cyclophosphamine. Am J Hematol. 1976;1(1):97-104.
72. Quiquandon I, Fenaux P, Caulier MT, Pagniez D, Huart JJ, Bauters F. Re-evaluation of the role of azathioprine in the treatment of adult chronic idiopathic thrombocytopenic purpura: a report on 53 cases. Br J Haematol. 1990;74(2):223-228.
73. Sussman LN. Azathioprine in refractory idiopathic thrombocytopenic purpura. JAMA. 1967;202(4):259-263.
74. Goebel KM, Gassel WD, Goebel FD. Evaluation of azathioprine in autoimmune thrombocytopenia and lupus erythematosus. Scand J Haematol. 1973;10(1):28-34.
75. Sobota A, Neufeld EJ, Lapsia S, Bennett CM. Response to mercaptopurine for refractory autoimmune cytopenias in children. Pediatr Blood Cancer. 2009;52(1):80-84.
76. Taylor A, Neave L, Solanki S, et al. Mycophenolate mofetil therapy for severe immune thrombocytopenia. Br J Haematol. 2015;171(4):625-630.
77. Colović M, Suvajdzic N, Colović N, Tomin D, Vidović A, Palibrk V. Mycophenolate mophetil therapy for chronic immune thrombocytopenic purpura resistant to steroids, immunosuppressants, and/or splenectomy in adults. Platelets. 2011;22(2):153-156.
78. Provan D, Moss AJ, Newland AC, Bussel JB. Efficacy of mycophenolate mofetil as single-agent therapy for refractory immune thrombocytopenic purpura. Am J Hematol. 2006;81(1):19-25.
79. Zhang WG, Ji L, Cao XM, et al. Mycophenolate mofetil as a treatment for refractory idiopathic thrombocytopenic purpura. Acta Pharmacol Sin. 2005;26(5):598-602.
80. Kotb R, Pinganaud C, Trichet C, et al. Efficacy of mycophenolate mofetil in adult refractory autoimmune cytopenias: a single center preliminary study. Eur J Haematol. 2005;75(1):60-64.
81. Howard J, Hoffbrand AV, Prentice HG, Mehta A. Mycophenolate mofetil for the treatment of refractory auto-immune haemolytic anaemia and auto-immune thrombocytopenia purpura. Br J Haematol. 2002;117(3):712-715.
82. Hou M, Peng J, Shi Y, et al. Mycophenolate mofetil (MMF) for the treatment of steroid-resistant idiopathic thrombocytopenic purpura. Eur J Haematol. 2003;70(6):353-357.
83. Zver S, Zupan IP, Cernelc P. Cyclosporin A as an immunosuppressive treatment modality for patients with refractory autoimmune thrombocytopenic purpura after splenectomy failure. Int J Hematol. 2006;83(3):238-242.
84. Perrotta S, Amendola G, Locatelli F, et al. Treatment with short-term, high-dose cyclosporin A in children with refractory chronic idiopathic thrombocytopenic purpura. Br J Haematol. 2003;121(1):143-147.
85. Kappers-Klunne MC, van't Veer MB. Cyclosporin A for the treatment of patients with chronic idiopathic thrombocytopenic purpura refractory to corticosteroids or splenectomy. Br J Haematol. 2001;114(1):121-125.
86. Dai L, Zhang R, Wang Z, et al. Efficacy of immunomodulatory therapy with all-trans retinoid acid in adult patients with chronic immune thrombocytopenia. Thromb Res. 2016;140:73-80.
87. Huhn RD, Fogarty PF, Nakamura R, et al. High-dose cyclophosphamide with autologous lymphocyte-depleted peripheral blood stem cell (PBSC) support for treatment of refractory chronic autoimmune thrombocytopenia. Blood. 2003;101(1):71-77.
88. Strother SV, Zuckerman KS, LoBuglio AF. Colchicine therapy for refractory idiopathic thrombocytopenic purpura. Arch Intern Med. 1984;144(11):2198-2200.
89. Donato H, Kohan R, Picón A, et al. Alpha-interferon therapy induces improvement of platelet counts in children with chronic idiopathic thrombocytopenic purpura. J Pediatr Hematol Oncol. 2001;23(9):598-603.
90. Fujimura K, Takafuta T, Kuriya S, et al. Recombinant human interferon alpha-2b (rh IFN alpha-2b) therapy for steroid resistant idiopathic thrombocytopenic purpura (ITP). Am J Hematol. 1996;51(1):37-44.
91. Dubbeld P, Hillen HF, Schouten HC. Interferon treatment of refractory idiopathic thrombocytopenic purpura (ITP). Eur J Haematol. 1994;52(4):233-235.
92. Proctor SJ, Jackson G, Carey P, et al. Improvement of platelet counts in steroid-unresponsive idiopathic immune thrombocytopenic purpura after short-course therapy with recombinant alpha 2b interferon. Blood. 1989;74(6):1894-1897.
93. Buskard N, Rock G, Nair R; Canadian Apheresis Group. The Canadian experience using plasma exchange for immune thrombocytopenic purpura. Transfus Sci. 1998;19(3):295-300.
94. Blanchette VS, Hogan VA, McCombie NE, et al. Intensive plasma exchange therapy in ten patients with idiopathic thrombocytopenic purpura. Transfusion. 1984;24(5):388-394.
95. Marder VJ, Nusbacher J, Anderson FW. One-year follow-up of plasma exchange therapy in 14 patients with idiopathic thrombocytopenic purpura. Transfusion. 1981;21(3):291-298.
96. Snyder HW Jr, Cochran SK, Balint JP Jr, et al. Experience with protein A-immunoadsorption in treatment-resistant adult immune thrombocytopenic purpura. Blood. 1992;79(9):2237-2245.
97. Jubelirer SJ. Pilot study of ascorbic acid for the treatment of refractory immune thrombocytopenic purpura. Am J Hematol. 1993;43(1):44-46.
98. van der Beek-Boter JW, van Oers MH, von dem Borne AE, Klaassen RJ. Ascorbate for the treatment of ITP. Eur J Haematol. 1992;48(1):61-62.
99. Brox AG, Howson-Jan K, Fauser AA. Treatment of idiopathic thrombocytopenic purpura with ascorbate. Br J Haematol. 1988;70(3):341-344.
100. Verhoef GE, Boonen S, Boogaerts MA. Ascorbate for the treatment of refractory idiopathic thrombocytopenic purpura. Br J Haematol. 1990;74(2):234-235.